雅培Q3营收/EPS微超预期，但下调全年可比销售增长指引至约6%，盘前一度跌超4%

Abbott Laboratories ( ABT ) slipped in premarket trading on Wednesday after the MedTech giant lowered its full-year growth outlook with its Q3 2026 results amid plans to separate its nutrition business. However, its Q3 results topped estimates, as revenue reached $13.0B with a ~14.5% YoY growth exceeding the consensus by $20M, while its Nutrition and Diagnostics units offset weakness in its MedTech and Established Pharmaceuticals segments. Abbott’s ( ABT ) nutrition and diagnostics sales reached $2.26B and $3.31B, exceeding the Street forecasts of $2.21B and $3.28B, respectively, according to Bloomberg data. However, its MedTech and Pharma sales stood at $5.83B and $1.61B, compared with $5.88B and $1.62B in the consensus. The company’s adjusted earnings per share, meanwhile, improved ~9% YoY to $1.42, topping estimates by $0.01 as its gross margin rose to ~57% from ~56% in the prior-year period. Looking ahead, Abbott ( ABT ) projected its 2026 adjusted EPS to reach $5.50 - $5.55 compared with $5.45 - $5.60 in the prior forecast and set its full-year outlook for comparable sales growth at about 6% down from 6.5% - 7.5% previously. Before the earnings release, the company announced plans to separate its Neutrition segment as an independent public company by the end of 2027, a transaction it said will impact its 2026 and 2027 outlook.